The impact of expansion of sirolimus eluting stent on intimal hyperplasia: an intravascular ultrasound study.
- Author:
Rui-yan ZHANG
1
;
Wei-feng SHEN
;
Jian-sheng ZHANG
;
Zhen-kun YANG
;
Qi ZHANG
;
Jian HU
;
Yue-hua FANG
Author Information
- Publication Type:Journal Article
- MeSH: Coronary Angiography; Coronary Artery Disease; diagnostic imaging; pathology; therapy; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Hyperplasia; pathology; Male; Middle Aged; Sirolimus; administration & dosage; Tunica Intima; pathology; Ultrasonography, Interventional
- From: Chinese Journal of Cardiology 2006;34(4):341-344
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the impact of expansion grade of sirolimus eluting stent on intimal hyperplasia with intravascular ultrasound (IVUS).
METHODSA total of 75 patients implanted with sirolimus eluting stents for at least 8 months were enrolled in this study and IVUS could be performed in 76 stents of 73 patients and 2 patients were excluded due to total coronary occlusion. External elastic membrane (EEM) cross-sectional areas (CSA) at stent inlet and outlet, at in-stent minimal CSA; in-stent CSA, cavity CSA, intimal area (in-stent area-cavity area), maximal and minimal diameter of stent, and symmetry index of stent (minimal diameter of stent/maximal diameter of stent) were measured.
RESULTFive out of 76 stents of 73 patients developed intimal hyperplasia and intimal proliferation was inhibited by sirolimus eluting stent in patients with either minimal stent CSA/EEM CSA < 0.5 (n = 56) or >or= 0.5 (n = 20), minimal stent CSA/reference CSA < 0.9 (n = 44) or >or= 0.9 (n = 32), minimal stent CSA < 5 mm(2) (n = 25) or CSA >or= 5 mm(2) (n = 51), symmetry index of stent at minimal CSA of stent < 0.9 (n = 37) or >or= 0.9 (n = 39) during IVUS follow up.
CONCLUSIONSirolimus eluting stent inhibited intimal hyperplasia independent of stent expansion grade.
